Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139


Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.

Salgado TM, Quinn CS, Krumbach EK, Wenceslao I, Gonzalez M, Reed HL, Syverson JG, Etz RS, Vangipuram K, Barker MR, Henry NL, Farris KB, Hertz DL.

Support Care Cancer. 2020 Jan 2. doi: 10.1007/s00520-019-05254-6. [Epub ahead of print]


Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy.

Marcath LA, Kidwell KM, Vangipuram K, Gersch CL, Rae JM, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Smith EML, Henry NL, Beutler AS, Hertz DL.

Br J Clin Pharmacol. 2019 Dec 10. doi: 10.1111/bcp.14192. [Epub ahead of print]


Reply to A. Katz.

Henry NL, Andre F, Ismaila N, Somerfield MR, Stearns V.

J Clin Oncol. 2020 Jan 1;38(1):102-103. doi: 10.1200/JCO.19.02431. Epub 2019 Nov 1. No abstract available.


Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage Breast Cancer: Update Summary of ASCO Cancer Care Ontario Guideline Endorsement.

Henry NL, Somerfield MR, Stearns V.

J Oncol Pract. 2019 Nov;15(11):599-602. doi: 10.1200/JOP.19.00266. Epub 2019 Jul 23. No abstract available.


Ovarian remnant syndrome in an aromatase inhibitor-treated patient with BRCA2 mutation following bilateral oophorectomy.

Wei M, Maurer KA, Henry NL.

Breast J. 2019 Nov;25(6):1254-1256. doi: 10.1111/tbj.13454. Epub 2019 Jul 4.


Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.

Henry NL, Somerfield MR, Abramson VG, Ismaila N, Allison KH, Anders CK, Chingos DT, Eisen A, Ferrari BL, Openshaw TH, Spears PA, Vikas P, Stearns V.

J Clin Oncol. 2019 Aug 1;37(22):1965-1977. doi: 10.1200/JCO.19.00948. Epub 2019 Jun 17.


Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.

Dempsey JM, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, Hertz DL.

Pharmacogenomics. 2019 Jun;20(8):571-580. doi: 10.2217/pgs-2019-0020.


Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.

Andre F, Ismaila N, Henry NL, Somerfield MR, Bast RC, Barlow W, Collyar DE, Hammond ME, Kuderer NM, Liu MC, Van Poznak C, Wolff AC, Stearns V.

J Clin Oncol. 2019 Aug 1;37(22):1956-1964. doi: 10.1200/JCO.19.00945. Epub 2019 May 31.


Breast cancer histologic subtypes show excess familial clustering.

Henry NL, Cannon-Albright LA.

Cancer. 2019 Sep 15;125(18):3131-3138. doi: 10.1002/cncr.32198. Epub 2019 May 23.


Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.

Sheng JY, Blackford AL, Bardia A, Venkat R, Rosson G, Giles J, Hayes DF, Jeter SC, Zhang Z, Hayden J, Nguyen A, Storniolo AM, Tarpinian K, Henry NL, Stearns V.

Breast Cancer Res Treat. 2019 Aug;176(3):617-624. doi: 10.1007/s10549-019-05270-4. Epub 2019 May 11.


A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer.

Stewart RL, Updike KL, Factor RE, Henry NL, Boucher KM, Bernard PS, Varley KE.

Cancer Res. 2019 Jul 1;79(13):3466-3478. doi: 10.1158/0008-5472.CAN-18-3014. Epub 2019 May 2.


Association between body mass index and response to duloxetine for aromatase inhibitor-associated musculoskeletal symptoms in SWOG S1202.

Henry NL, Unger JM, Till C, Schott AF, Crew KD, Lew DL, Fisch MJ, Moinpour CM, Wade JL 3rd, Hershman DL.

Cancer. 2019 Jun 15;125(12):2123-2129. doi: 10.1002/cncr.32024. Epub 2019 Mar 12.


Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion.

Kamdem LK, Xi J, Clark BL, Gregory BJ, Kidwell KM, Storniolo AM, Stearns V, Hayes DF, Gersch CL, Rae JM, Henry NL, Hertz DL.

Breast Cancer Res Treat. 2019 Jun;175(2):297-303. doi: 10.1007/s10549-019-05158-3. Epub 2019 Feb 12.


Factors influencing the use of extended adjuvant endocrine therapy.

Kadakia KC, Kidwell KM, Barton DL, Schott AF, Hayes DF, Griggs JJ, Henry NL.

Breast Cancer Res Treat. 2019 May;175(1):181-189. doi: 10.1007/s10549-019-05145-8. Epub 2019 Jan 31.


Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Pal SK, Miller MJ, Agarwal N, Chang SM, Chavez-MacGregor M, Cohen E, Cole S, Dale W, Magid Diefenbach CS, Disis ML, Dreicer R, Graham DL, Henry NL, Jones J, Keedy V, Klepin HD, Markham MJ, Mittendorf EA, Rodriguez-Galindo C, Sabel MS, Schilsky RL, Sznol M, Tap WD, Westin SN, Johnson BE.

J Clin Oncol. 2019 Apr 1;37(10):834-849. doi: 10.1200/JCO.18.02037. Epub 2019 Jan 31. No abstract available.


Pilot Study of an Internet-Based Self-Management Program for Symptom Control in Patients With Early-Stage Breast Cancer.

Henry NL, Kidwell KM, Alsamarraie C, Bridges CM, Kwiatkowski C, Clauw DJ, Smith EML, Williams DA.

JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.17.00106.


Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure.

Marcath LA, Kidwell KM, Robinson AC, Vangipuram K, Burness ML, Griggs JJ, Poznak CV, Schott AF, Hayes DF, Henry NL, Hertz DL.

Pharmacogenomics. 2019 Jan;20(2):95-104. doi: 10.2217/pgs-2018-0162. Epub 2018 Dec 6.


Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?

Sparano JA, Henry NL.

J Natl Cancer Inst. 2019 Apr 1;111(4):339-341. doi: 10.1093/jnci/djy153. No abstract available.


Integrative Oncology Scholars Program: A Model for Integrative Oncology Education.

Zick SM, Czuhajewski C, Fouladbakhsh JM, Greenlee H, Harris RE, Henry NL, Jolly S, Khabir T, Perlmutter J, Remington T, Snyder D, Spratke L, Zebrack B, Zettell E, Benn R.

J Altern Complement Med. 2018 Sep/Oct;24(9-10):1018-1022. doi: 10.1089/acm.2018.0184.


Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).

Shen S, Unger JM, Crew KD, Till C, Greenlee H, Gralow J, Dakhil SR, Minasian LM, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL.

Breast Cancer Res Treat. 2018 Dec;172(3):603-610. doi: 10.1007/s10549-018-4946-0. Epub 2018 Aug 29.


Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Clinical Trial.

Hershman DL, Unger JM, Greenlee H, Capodice JL, Lew DL, Darke AK, Kengla AT, Melnik MK, Jorgensen CW, Kreisle WH, Minasian LM, Fisch MJ, Henry NL, Crew KD.

JAMA. 2018 Jul 10;320(2):167-176. doi: 10.1001/jama.2018.8907.


Pharmacometabolomics reveals a role for histidine, phenylalanine, and threonine in the development of paclitaxel-induced peripheral neuropathy.

Sun Y, Kim JH, Vangipuram K, Hayes DF, Smith EML, Yeomans L, Henry NL, Stringer KA, Hertz DL.

Breast Cancer Res Treat. 2018 Oct;171(3):657-666. doi: 10.1007/s10549-018-4862-3. Epub 2018 Jun 26.


The Effect of the 2009 USPSTF breast cancer screening recommendations on breast cancer in Michigan: A longitudinal study.

Caughran J, Braun TM, Breslin TM, Smith DR, Kreinbrink JL, Parish GK, Davis AT, Bacon-Baguley TA, Silver SM, Henry NL.

Breast J. 2018 Sep;24(5):730-737. doi: 10.1111/tbj.13034. Epub 2018 May 21.


A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 Aug;171(1):121-129. doi: 10.1007/s10549-018-4811-1. Epub 2018 May 11.


Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy.

Hertz DL, Kidwell KM, Vangipuram K, Li F, Pai MP, Burness M, Griggs JJ, Schott AF, Van Poznak C, Hayes DF, Lavoie Smith EM, Henry NL.

Clin Cancer Res. 2018 Aug 1;24(15):3602-3610. doi: 10.1158/1078-0432.CCR-18-0656. Epub 2018 Apr 27.


Disparities in cancer survival and incidence by metropolitan versus rural residence in Utah.

Hashibe M, Kirchhoff AC, Kepka D, Kim J, Millar M, Sweeney C, Herget K, Monroe M, Henry NL, Lopez AM, Mooney K.

Cancer Med. 2018 Apr;7(4):1490-1497. doi: 10.1002/cam4.1382. Epub 2018 Mar 13.


Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.

Bhave MA, Speth KA, Kidwell KM, Lyden A, Alsamarraie C, Murphy SL, Henry NL.

Clin Breast Cancer. 2018 Apr;18(2):168-174.e2. doi: 10.1016/j.clbc.2017.12.012. Epub 2017 Dec 27.


Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.

Dempsey JM, Xi J, Henry NL, Rae JM, Hertz DL.

Physiol Genomics. 2018 Feb 1;50(2):98-99. doi: 10.1152/physiolgenomics.00085.2017. Epub 2017 Dec 8.


Integrating clinicopathologic and genomic tools in chemotherapy decision-making for early stage breast cancer.

Havard R, Henry NL.

Future Oncol. 2017 Dec;13(28):2507-2510. doi: 10.2217/fon-2017-0452. Epub 2017 Nov 23. No abstract available.


Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202.

Henry NL, Unger JM, Schott AF, Fehrenbacher L, Flynn PJ, Prow DM, Sharer CW, Burton GV, Kuzma CS, Moseley A, Lew DL, Fisch MJ, Moinpour CM, Hershman DL, Wade JL 3rd.

J Clin Oncol. 2018 Feb 1;36(4):326-332. doi: 10.1200/JCO.2017.74.6651. Epub 2017 Nov 14.


Variable aromatase inhibitor plasma concentrations do not correlate with circulating estrogen concentrations in post-menopausal breast cancer patients.

Hertz DL, Speth KA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Breast Cancer Res Treat. 2017 Oct;165(3):659-668. doi: 10.1007/s10549-017-4346-x. Epub 2017 Jun 22.


Standard and Genomic Tools for Decision Support in Breast Cancer Treatment.

Henry NL, Bedard PL, DeMichele A.

Am Soc Clin Oncol Educ Book. 2017;37:106-115. doi: 10.14694/EDBK_175617. Review.


Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.

Kadakia KC, Kidwell KM, Seewald NJ, Snyder CF, Storniolo AM, Otte JL, Flockhart DA, Hayes DF, Stearns V, Henry NL.

Breast Cancer Res Treat. 2017 Jul;164(2):411-419. doi: 10.1007/s10549-017-4260-2. Epub 2017 Apr 27.


Associations Between Patient and Anthropometric Characteristics and Aromatase Inhibitor Discontinuation.

Henry NL, Speth K, Lintermans A, Kidwell KM, Carlson R, Hayes DF, Neven P.

Clin Breast Cancer. 2017 Aug;17(5):350-355.e4. doi: 10.1016/j.clbc.2017.03.002. Epub 2017 Mar 11.


Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.

Hertz DL, Henry NL, Rae JM.

Pharmacogenomics. 2017 Apr;18(5):481-499. doi: 10.2217/pgs-2016-0205. Epub 2017 Mar 27. Review.


Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registry.

Henry NL, Braun TM, Breslin TM, Gorski DH, Silver SM, Griggs JJ.

Cancer. 2017 Aug 1;123(15):2975-2983. doi: 10.1002/cncr.30674. Epub 2017 Mar 16.


Extended Endocrine Therapy: Is 5 Years Enough?

Bhave MA, Henry NL.

Curr Oncol Rep. 2017 Mar;19(3):16. doi: 10.1007/s11912-017-0576-7. Review.


Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.

Salgado TM, Davis EJ, Farris KB, Fawaz S, Batra P, Henry NL.

Breast Cancer Res Treat. 2017 Jun;163(2):311-319. doi: 10.1007/s10549-017-4177-9. Epub 2017 Mar 1.


Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL.

Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9.


Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.

Henry NL, Braun TM, Ali HY, Munir K, Silver SM, Gorski DH, Breslin TM, Griggs JJ.

Cancer. 2017 May 15;123(6):948-956. doi: 10.1002/cncr.30429. Epub 2016 Oct 27.


Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Breast Cancer Res Treat. 2016 Nov;160(2):297-304. Epub 2016 Oct 4.


Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.

Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23.


ESR1 and PGR polymorphisms are associated with estrogen and progesterone receptor expression in breast tumors.

Hertz DL, Henry NL, Kidwell KM, Thomas D, Goddard A, Azzouz F, Speth K, Li L, Banerjee M, Thibert JN, Kleer CG, Stearns V, Hayes DF, Skaar TC, Rae JM.

Physiol Genomics. 2016 Sep 1;48(9):688-98. doi: 10.1152/physiolgenomics.00065.2016. Epub 2016 Aug 19.


The pathway to clinical use of a cancer biomarker.

Henry NL.

Scand J Clin Lab Invest Suppl. 2016;245:S17-21. doi: 10.1080/00365513.2016.1206441. Epub 2016 Jul 13. Review.


Initial founders of captive populations are genetically representative of natural populations in critically endangered dusky gopher frogs, Lithobates sevosus.

Hinkson KM, Henry NL, Hensley NM, Richter SC.

Zoo Biol. 2016 Sep;35(5):378-384. doi: 10.1002/zoo.21309. Epub 2016 Jul 6.


Associations between metabolic syndrome, breast cancer recurrence, and the 21-gene recurrence score assay.

Muniz J, Kidwell KM, Henry NL.

Breast Cancer Res Treat. 2016 Jun;157(3):597-603. doi: 10.1007/s10549-016-3846-4. Epub 2016 Jun 6.


Heterogeneous estrogen receptor expression in circulating tumor cells suggests diverse mechanisms of fulvestrant resistance.

Paoletti C, Larios JM, Muñiz MC, Aung K, Cannell EM, Darga EP, Kidwell KM, Thomas DG, Tokudome N, Brown ME, Connelly MC, Chianese DA, Schott AF, Henry NL, Rae JM, Hayes DF.

Mol Oncol. 2016 Aug;10(7):1078-85. doi: 10.1016/j.molonc.2016.04.006. Epub 2016 Apr 29.


Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes.

Kang Q, Henry NL, Paoletti C, Jiang H, Vats P, Chinnaiyan AM, Hayes DF, Merajver SD, Rae JM, Tewari M.

Clin Biochem. 2016 Dec;49(18):1354-1360. doi: 10.1016/j.clinbiochem.2016.03.012. Epub 2016 Apr 27.


Adjuvant endocrine therapy in premenopausal women with breast cancer.

Kadakia KC, Henry NL.

Clin Adv Hematol Oncol. 2015 Oct;13(10):663-72.


Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.

Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL.

Oncologist. 2016 May;21(5):539-46. doi: 10.1634/theoncologist.2015-0349. Epub 2016 Mar 23.

Supplemental Content

Loading ...
Support Center